long-term survival

FDA Advisory Panel Votes Against AstraZeneca's Breast Cancer Drug Camizestrant

AstraZeneca's experimental breast cancer drug camizestrant faced a setback as a U.S. FDA advisory panel voted 6-3 against approval, citing concerns over the SERENA-6 trial design. The Phase 3 trial showed a 56% reduction in disease progression or death, but panel members weren't convinced early switching improved long-term survival. Shares fell 2% in morning trading, though analysts noted the drug's efficacy wasn't dismissed and the issue shouldn't impact AstraZeneca's $80 billion 2030 sales goal.